AFP
SRNE

Ausdal Financial Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ausdal Financial Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$31K – 513
2021
Q2 		$31K Buy
+10,000
New +$79.6K ﹤0.01% 460

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ausdal Financial Partners's SRNE Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2016, closing a stake of 600 shares — an estimated $5K sold.

Ausdal Financial Partners first reported a position in SRNE in Q4 2015 and held it in 1 quarter. The position peaked at $5K in Q4 2015. 68 funds tracked by Wall St. Rank hold SRNE as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 600 Sorrento Therapeutics, Inc. shares in Q1 2016, an estimated $5K.
  • Ausdal Financial Partners first reported a position in Sorrento Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Sorrento Therapeutics, Inc. position peaked at $5K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.